Melane Sampson, Author at BioTuesdays

Executive Moves

Therma Bright adds pharma veteran Douglas S. Sommerville to AB

Therma Bright (TSXV: THRM; OTCQB: TBRIF), has announced the addition of Douglas S. Sommerville to its advisory board. In a statement, Rob Fia, CEO of Therma Bright, said, “Doug is highly respected across North...

September 12, 2024

Executive Moves

Creyon Bio appoints venture capitalists Serge Messerlian and Shaquille Vayda to board

Creyon Bio has appointed two prominent venture capitalists, Serge Messerlian, operating partner at DCVC Bio, and Shaquille Vayda, principal at Lux Capital, to its board. “We are excited to welcome Serge and Shaq...

September 10, 2024

Developments

Vor Bio reports data validating shielded transplants and early evidence of patient benefit

Vor Bio (NASDAQ:NOR) announced new data from its ongoing Phase 1/2 study of VBP101 in relapsed/refractory AML patients, demonstrating reliable engraftment, shielding from Mylotarg toxicity, a broadened therapeutic...

September 6, 2024

Developments

Ocuphire doses first participants in Phase 3 presbyopia study

Ocuphire Pharma (NASDAQ:OCUP) has initiated its VEGA-3 Phase 3 trial, evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia, with its first dose. Topline results are expected in the first half of 2025...

September 6, 2024

Developments

NIH awards TransCode with $2 million grant for lead therapeutic

TransCode Therapeutics (NASDAQ:RNAZ) announced that the National Institutes of Health (NIH) has awarded the company a $2 million Direct to Phase II Small Business Innovation Research grant to support the clinical...

September 5, 2024

Developments

Valneva and Pfizer announce positive Phase 2 data for Lyme disease booster candidate

Valneva SE (NASDAQ:VALN) and Pfizer (NYSE:PFE) have announced positive Phase II immunogenicity and safety data from a second booster dose of the VLA15 Lyme disease vaccine candidate, administered one year after the...

September 3, 2024

Developments

Praxis reports positive topline results from study of relutrigine in developmental epilepsies

Praxis Precision Medicines (NASDAQ:PRAX) has announced positive topline results from its EMBOLD Phase II proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy...

September 3, 2024

Feature

Model Medicines innovates by bringing together data science and biology to develop drugs

Closely-held Model Medicines is spearheading the use of AI to model chemistry and human biology, empowering drug discovery and creating novel, best-in-class therapeutics for diseases with high unmet medical needs at...

September 3, 2024

Developments

Nuvectis receives FDA orphan drug designation for NXP800 targeting cancer

The FDA granted orphan drug designation (ODD) to Nuvectis Pharma’s (NASDAQ:NVCT) oral GCN2 activator, NXP800, for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. The ODD could...

August 30, 2024

Developments

Ventyx announces CFO departure and launches search for successor

Ventyx Biosciences (NASDAQ:VTYX) announced the departure of Martin Auster, M.D., as CFO, effective August 30, 2024, and has initiated a search for his successor. The company’s SVP of finance, Ron Gonzales, CPA, MBA, has...

August 30, 2024

Author - Melane Sampson

Therma Bright adds pharma veteran Douglas S. Sommerville to AB

Creyon Bio appoints venture capitalists Serge Messerlian and Shaquille Vayda to board

Vor Bio reports data validating shielded transplants and early evidence of patient benefit

Ocuphire doses first participants in Phase 3 presbyopia study

NIH awards TransCode with $2 million grant for lead therapeutic

Valneva and Pfizer announce positive Phase 2 data for Lyme disease booster candidate

Praxis reports positive topline results from study of relutrigine in developmental epilepsies

Model Medicines innovates by bringing together data science and biology to develop drugs

Nuvectis receives FDA orphan drug designation for NXP800 targeting cancer

Ventyx announces CFO departure and launches search for successor

General

More